PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease ReportsThrombocytopenic purpura idiopathic
MeSH D016553 - thrombocytopenic purpura idiopathic
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D011696:Thrombocytopenic purpura
$
Success rate
D001327:Autoimmune diseases
$
Success rate
D006474:Hemorrhagic disorders
$
Success rate
D016553: 
Thrombocytopenic purpura idiopathic
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaDexamethasone Dexamethasone  1990-08-31   
Cyclophosphamide Neosar  1993-04-29   
Prednisone Prednisone  1982-01-01   
PadagisDexamethasone, Neomycin, Polymyxin b Neomycin Polymyxin B Sulfates Dexamethasone  1989-07-31   
Dexamethasone, Tobramycin Tobramycin Dexamethasone  2022-02-11   
Dr Reddys LaboratoriesCyclophosphamide Cyclophosphamide 2036-02-15 2020-07-30   
Dexamethasone, Ciprofloxacin Ciprofloxacin Dexamethasone  2020-08-10   
Dexamethasone Dexamethasone  1986-04-09   
Prednisone Prednisone  2025-10-01   
MylanDexamethasone Dexamethasone  2008-08-29   
Prednisone Prednisone  1982-01-01   
CiplaCyclophosphamide Cyclophosphamide  2019-01-18   
SandozDexamethasone Dexamethasone  1985-01-16   
Dexamethasone, Neomycin, Polymyxin b Maxitrol  1984-05-22   
Dexamethasone, Ciprofloxacin Ciprodex 2025-06-04 2003-07-18   
Cyclophosphamide Cyclophosphamide  2023-09-12   
Dexamethasone, Tobramycin Tobradex  1988-08-18   
AiPing PharmaceuticalPrednisone Prednisone  1982-01-01   
AbbVieDexamethasone Ozurdex 2023-01-09 2009-06-17 $485 M Q4/24-Q3/25 
NovartisDexamethasone, Neomycin, Polymyxin b Dexacidin  1984-10-29   
Eltrombopag olamine Promacta 2022-11-20 2008-11-20 $2,163 M Q2/22-Q2/25 
Eltrombopag Revolade  2010-03-11   
Dexamethasone, Tobramycin Tobradex  1988-09-28   
WyethDexamethasone Dexamethasone  1982-01-01   
1
2
3
4
5
6
...
11
>
Clinical Trials
Historical Success Rate
Phase 1
67%
16/24
Phase 2
59%
23/39
Phase 3
63%
27/43
Approved: 12Overall Success rate: 25%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
AbbVie
1
2
3
4
5
6
...
8
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use